medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2023, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2023; 21 (4)

Bullous pemphigoid probably triggered by COVID-19 vaccine

Acosta MMJ, Calderón SL, Bayona D’VJS, Llamas CBC, Rolón CMC

Language: Spanish
References: 10
Page: 318-322
PDF size: 296.68 Kb.


ABSTRACT

We present two cases who were admitted to the emergency room due to the painful blisters and the extensive affection of the body surface. Both cases had in common the application of COVID-19 vaccine prior to the dermatological lesions. The cases were evaluated by dermatology, considering a clinical diagnosis of bullous pemphigoid, and confirmed by basic skin biopsy and immunofluorescence. Both treated with immunosuppressive management with improvement in skin compromise, but died due to complications of underlying comorbidities. We discuss the possible mechanisms involved in the development of this pathology.


REFERENCES

  1. Pérez-López I, Moyano-Bueno D y Ruiz-Villaverde R, Bullouspemphigoid and covid-19 vaccine, Med Clin (Barcelona) 2021;157(10):e333-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34119340/.

  2. Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ yLehman JS, Subepithelial autoimmune blistering dermatoses:clinical features and diagnosis, J Am Acad Dermatol 2021; 85(1):1-14. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33684496/.

  3. Agharbi FZ, Eljazouly M, Basri G, Faik M, Benkirane A, AlbouzidiA et al., Bullous pemphigoid induced by the AstraZeneca covid-19 vaccine, Ann Dermatol Venereol 2022; 149(1):56-7. Disponibleen: https://pubmed.ncbi.nlm.nih.gov/34686374/.

  4. Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA yKim RH, Clinical and histopathological spectrum of delayed adversecutaneous reactions following covid-19 vaccination, J CutanPathol 2022; 49(1):34-41. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34292611/.

  5. Miyamoto D, Santi CG, Aoki V y Maruta CW, Bullous pemphigoid,An Bras Dermatol 2019; 94(2):133-46. Disponible en: http://journal.anaisdedermatologia.org.br/en-bullous-pemphigoidarticulo-S0365059620305778.

  6. McMahon DE, Kovarik CL, Damsky W, Rosenbach M, Lipoff JB,Tyagi A et al., Clinical and pathologic correlation of cutaneouscovid-19 vaccine reactions including v-repp: a registry-basedstudy, J Am Acad Dermatol 2022; 86(1):113-21. Disponible en:https://pubmed.ncbi.nlm.nih.gov/34517079/.

  7. Tomayko MM, Damsky W, Fathy R, McMahon DE, Turner N,Valentin MN et al., Subepidermal blistering eruptions, includingbullous pemphigoid, following covid-19 vaccination, J Allergy ClinImmunol 2021; 148(3):750-1. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34275656/.

  8. Schmidt V, Blum R y Möhrenschlager M, Biphasic bullous pemphigoidstarting after first dose and boosted by second doseof mrna-1273 vaccine in an 84-year-old female with polymorbidityand polypharmacy, J Eur Acad Dermatology Venereol 2022;36(2):e88-90. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.17722.

  9. Damiani G, Pacifico A, Pelloni F e Iorizzo M, The first dose ofcovid-19 vaccine may trigger pemphigus and bullous pemphigoidflares: is the second dose therefore contraindicated?, J EurAcad Dermatol Venereol 2021; 35(10):e645-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34169578/.

  10. Young J, Mercieca L, Ceci M, Pisani D, Betts A y Boffa MJ,A case of bullous pemphigoid after the sars-cov-2 mrna vaccine,J Eur Acad Dermatol Venereol 2022; 36(1):e13-6. Disponible en:https://pubmed.ncbi.nlm.nih.gov/34547137/.




2020     |     www.medigraphic.com